The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

A study measures the long-term downside of prostate cancer screening

A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment.1 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Otis W. Brawley, MD, MACP
Bloomberg Distinguished Professor of Oncology and Epidemiology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Table of Contents

YOU MAY BE INTERESTED IN

Obituary

Feng’s team advanced the understanding of biomarkers in prostate cancer

The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.
By NRG Staff

ACS report: Cancer mortality continues to drop despite rising incidence in women

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
By Yiqing Wang
Byline
Otis W. Brawley, MD, MACP
Bloomberg Distinguished Professor of Oncology and Epidemiology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account